A Phase 1/2 interventional study of chatbot in Opiate-Related Disorders and Opiate Substitution Treatment, sponsored by Dimagi Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Dimagi Inc. · Phase 1/2, Interventional, and Health services research
The goal of this clinical trial is to learn if/how an AI chatbot can support patients who in recovery for substance use, specifically those who are receiving medication for opioid use disorder.
Can the chatbot help lower drug use? Can the chatbot help improve clinical appointment adherence? Can the chatbot help patients build self-efficacy in leading their own recovery journey? Will the chatbot help reduce workload burden for primary care teams? Can the chatbot serve as a safe, useful and engaging tool to support patients?
Researchers will investigate the effects of using a chatbot to support follow-up care for patients in opioid use recovery.
Participants will:
Dimagi Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will receive access to a chatbot for 12 weeks that can be used from a mobile device to support follow-up care and recovery needs.
Other: chatbot
Participants will: * Participate in a baseline session to complete an initial survey and get trained on using the chatbot * Use the chatbot for 12 weeks and submit a brief weekly survey to provide feedback * Complete a final survey to provide substance use and health information as well as give feedback on the experience using the chatbot * Allow access to a limited set of demographic, substance use and health information in electronic health record for study analyses and context.
Also known as: Suzy, conversational agent
Change in SUD severity
Addiction Severity Index (ASI) Drugs composite score; Scored 0-7 with higher scores indicating increasing severity
Time frame: 12 weeks
Change in psychological health (Anxiety)
General Anxiety Disorder-7 (GAD-7); scored 0-21 with higher scores indicating increasing anxiety
Time frame: 12 weeks
Change in psychological health (Depression)
Patient Health Questionnaire-8 (PHQ-8); scored 0-24 with higher scores indicating more severe depression
Time frame: 12 weeks
Change in self-efficacy for managing chronic conditions (Emotions)
PROMIS Short Form 8a (Managing Emotions); scored from 8-40 with higher scores indicating higher confidence managing emotions
Time frame: 12 weeks
Change in self-efficacy for managing chronic conditions (Social Interactions)
PROMIS Short Form 8a (Social Interactions); scored from 8-40 with higher scores indicating higher confidence with managing social interactions
Time frame: 12 weeks
Change in quality of life
World Health Organization Quality of Life (WHOQoL-BREF) Assessment; higher scores indicate higher quality of life
Time frame: 12 weeks
Change in social needs
Accountable Health Communities Health-Related Social Needs (AHC HRSN) screening; higher scores indicate higher unmet social needs
Time frame: 12 weeks
Chatbot usability
Chatbot Usability Questionnaire (CUQ); scored 0-100 with higher scores indicating higher usability
Time frame: End of 12 week intervention
User Satisfaction
Net Promoter Score (NPS); scored -100 to 100 with higher scores indicating higher user satisfaction
Time frame: End of 12 week intervention
Plan to share: No — This study will include sensitive data from a small sample of patients with experience with substance use therefore data will be reported in aggregate and only qualitative data collected from participants may be reported individually and anonymously.
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dimagi Inc.